Tumor suppressive role of miR-194-5p in glioblastoma multiforme

ZHAO ZHANG, BO LEI, HONGGANG WU, XIAOLI ZHANG and NIANDONG ZHENG

Department of Neurosurgery, The People's Hospital of Leshan City, Leshan, Sichuan 614000, P.R. China

Received September 10, 2016; Accepted May 26, 2017

DOI: 10.3892/mmr.2017.7826

Abstract. Glioblastoma multiforme (GBM) is defined by the World Health Organization as the most aggressive form of grade IV glioma, characterized by unrestrained cellular proliferation. microRNAs (miRs) serve important roles in the pathogenesis of GBM. However, the function of miR-194-5p in GBM remains unknown. In the present study, the miR-194-5p levels in GBM tissues and cells were evaluated using the reverse transcription-quantitative polymerase chain reaction. Cellular proliferation was tested by MTT analysis. Cellular apoptosis was analyzed by fluorescence-activated cell sorting. The protein level of insulin-like growth factor 1 receptor, the target gene of miR-194-5p, was evaluated by western blotting. The interaction between miR-194-5p and the target gene was confirmed by the dual-luciferase reporter assay. It was demonstrated that miR-194-5p inhibited cell growth and promoted apoptosis. In conclusion, the results of the present study indicated the tumor suppressive role of miR-194-5p.

Introduction

Glioblastoma multiforme (GBM) develops from the lineage of star-shaped glial cells (1). GBM presents a highly prevalent cancer, accounting for 12-15% of all brain tumors and ~70% of all diagnosed gliomas (2,3). GBM is defined by the World Health Organization as the most aggressive form of grade IV glioma, characterized by unrestrained cellular proliferation, strong resistance to apoptosis, diffuse infiltration, vigorous angiogenesis and widespread genomic instability (4). Annual new case of malignant glioma is ≥5/100,000 population (5). Currently, the clinical outcome of glioma has improved (6-8); however, the median survival rate of patients with GBM remains at only 12-15 months (9), thus, novel therapeutic targets are required.

Increasing evidence has confirmed that microRNAs (miRNAs/miRs) serve essential roles in the pathogenesis of various tumors. miRNAs are a class of small RNAs, ~18-22 nucleotides in length (10-12). miRNAs suppress protein expression through the inhibition of translation or the induction of mRNA degradation, by binding to the 3' untranslated region (3'UTR) of target miRNAs (13). miRNAs are involved in a diverse range of biological processes, including cellular proliferation, migration, apoptosis and differentiation (14-18).

The insulin-like growth factor (IGF) signaling axis is critical to the growth, development and maintenance of a number of tissue types (19,20). A previous study demonstrated that the IGF 1 receptor (IGF1R) is an independent prognostic factor associated with decreased survival time in patients with GBM (21). The present study investigated the role of miR-194-5p in GBM and identified IGF1R as a target of miR-194-5p. IGF1R may warrant further investigation as a potential novel therapeutic target.

Materials and methods

Patients and tissue samples. A total of 10 GBM tissues and 10 corresponding adjacent normal tissues were collected from the Department of Neurosurgery, The People's Hospital of Leshan City (Leshan, China). The use of human tissues in the present study was evaluated and approved by the Ethic Committee of The People's Hospital of Leshan City. All patients enrolled in the present study provided written informed consent, and all specimens were handled and made anonymous according to the ethical and legal standards of China. All GBM tissues were confirmed and evaluated by a pathologist, and were frozen at -80°C immediately following surgery.

Cell culture. The normal human astrocytes (NHA; cat. no. 43923), and human glioblastoma cell lines U373 and U118, were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). All cells were cultured in Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at 37°C with 5% CO₂. The U373 cell line is known to be contaminated with the U251 astrocytoma cell line and the U118 cell line is known to be contaminated with the U138 astrocytoma cell line (22).

Analysis of miR-194-5p in tissues and cell lines. Total RNA was extracted from cells using TRizol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. The level of miR-194-5p was evaluated using a TaqMan MiRNA Assay (Applied Biosystems; Thermo Fisher Scientific, Inc.) and a TaqMan MicroRNA Assay (Applied Biosystems; Thermo Fisher Scientific, Inc.). The assay was conducted using a ABI 7500 system (Applied Biosystems; Thermo Fisher Scientific, Inc.).
Fisher Scientific, Inc.), according to the manufacturer’s protocol. U6 small nuclear RNA was used as an internal loading control. Reverse transcription-quantitative polymerase chain reaction was performed on an ABI 7900HT instrument (Applied Biosystems; Thermo Fisher Scientific, Inc.). The primers were synthesized and tested by Sangon Biotech Co., Ltd. (Shanghai, China). The primer sequences were as follows: forward, GTGGACCGCACAAGCTCGCT, and reverse, TTGTGGAGGCGACTGTGATAGCA; miR-194-5p forward, AGTGTGACCTTGACATCCGT, and reverse, GCA GCTCAGTAACAGTCCGC. Relative miR-194-5p expression was calculated according to the comparative Cq method (23) and normalized to the expression of U6.

Overexpression and inhibition of miR-194-5p in vitro. miR-194-5p was overexpressed and inhibited in vitro by transfection with miR-194-5p mimics and an miR-194-5p antisense oligonucleotide (ASO), respectively. The miR-194-5p mimics and miR-194-5p ASO were purchased from Sangon Biotech Co., Ltd. The miRNA sequences were as follows: miR-194-5p mimic, 5’-AAGGCAAGGGCCCCGCUCCCC-3’; miR-194-5p ASO, 5’-GGAGCCGGGGCCCGUCUUU-3; scrambled miRNA control, 5’-CAUGACUUUUGUGUAGUCAA-3. The cells were seeded (1x10^5 cells/well) and cultured overnight. Transfection was performed for 30 min using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.), according to the manufacturer’s protocol.

Cellular proliferation assay. After 24, 48 and 72 h of transfection, cellular proliferation was assessed by the MTT assay. Cells were seeded into 96-well plates at a density of 5x10^3 cells/well. MTT reagent was added into the medium at a final concentration of 0.1 mg/ml. A total of 100 µl DMSO was added. Optical density was measured by a microplate reader at 570 nm.

Cellular apoptosis analysis. A cell suspension (5x10^5 cells/ml) was prepared in annexin V-fluorescein isothiocyanate (FITC; Abcam, Shanghai, China) binding buffer and Annexin V-FITC was added and incubated for 15 min at room temperature. Subsequently, propidium iodide (PI; Abcam, Shanghai, China) binding buffer and Annexin V-FITC were added. Optical density was measured by a microplate reader at 570 nm.

Prediction of the possible targets of miR-149-5p. Targetscan software (www.targetscan.org) was used to predict the potential targets of miR-149-5p.

Dual-luciferase reporter assays. Cells were seeded at 1x10^5 cells/well and were serum starved for 6 h prior to transfection. The wild-type (WT) 3'UTR of IGF1R and mutated controls were cloned and inserted into the dual-luciferase-reporter plasmid (500 ng; Shengong Biotechnology Company) and the pGL3-control (100 ng; Promega Corporation, Madison, WI, USA). miR-194-5p mimics and controls were subsequently transfected into U373 cells containing wild-type or mutant 3'UTR plasmids with Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Cells were harvested and luciferase activities were analyzed after 24 h using the Dual-luciferase Reporter assay system (Promega Corporation). The mutant IGF1R 3'UTRs were generated using a Site-Directed Mutagenesis kit (Promega Corporation). The primers used to perform mutagenesis were as follows: IGF1R forward, 5’-ctgctcctagcttgataagggcaatgactc-3’, and reverse, 5’-gaagtgcttgctgcgtcggacctagacag-3’. The kit was used according to the manufacturer’s protocol.

Western blot analysis. Whole-cell lysates were prepared as previously described (25). The cell lysates were centrifuged at 4°C, 12,000 x g for 10 min, and the proteins were quantified using a bicinchoninic acid protein quantification kit (cat. no. ab102536; Abcam, Cambridge, UK). Proteins (30 µg) were separated via 4-10% SDS-PAGE. Membranes were electrotransferred to nitrocellulose membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked with 5% non-fat milk overnight at 4°C and incubated with the anti-IGF1R antibody (cat. no. 3027; 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA) overnight at 4°C. β-actin (cat. no. 4967; 1:1,000; Cell Signaling Technology, Inc.) was used as the endogenous control, incubated overnight at 4°C. Then the membranes were incubated with an anti-rabbit horseradish peroxidase-conjugated secondary antibody (cat. no. 7074; 1:1,000; Cell Signaling Technology, Inc.) for 2 h at room temperature. The bands were visualized using enhanced chemiluminescence (GE Healthcare Life Sciences, Little Chalfont, UK).

Statistical analysis. Data are presented as the mean ± standard deviation of 3 independent experiments. Statistical analysis was performed using SPSS software (version 10.0; SPSS, Inc., Chicago, IL, USA). The difference between two groups was analyzed using a two-tailed Student’s t-test. One-way analysis of variance was used to analyze the difference between multiple groups, followed by the Student-Newman-Keuls method. P<0.05 was considered to indicate a statistically significant difference.

Results

miR-194-5p targets IGF1R. IGF1R is an independent prognostic factor associated with decreased survival of patients with GBM (21). Therefore, miR-194-5p was selected for investigation, as it was identified to target IGF1R. A total of three miR-194-5p binding sites were identified in the 3'UTR of the IGF1R gene and three mutants were subsequently generated (Fig. 1A). The three mutated versions of the IGF1R 3'UTRs were cloned into luciferase reporter plasmids. miR-194-5p mimics and the mutant 3'UTRs were cotransfected into U373 cells, and it was observed that the miR-194-5p mimics reduced the luciferase activity of the WT 3'UTR, while the mutated 3'UTRs partially reduced the inhibitory function of miR-194-5p, scrambled miRNA was used as a vehicle (Fig. 1B). miR-194-5p mimics were subsequently transfected into U373 cells and the IGF-1R protein
Figure 1. IGF1R is targeted by miR-194-5p in U373 cells. (A) The three miR-194-5p binding sites in IGF1R and the mutated sites are listed. (B) miR-194-5p mimics were transfected into U373 cells containing WT or mutant 3'UTR plasmids and a dual-luciferase reporter assay was performed. (C) Western blotting of IGF1R was performed following transfection with miR-194-5p. The data are presented as the mean ± standard deviation. Experiments were repeated at least three times. *P<0.05 vs. the vehicle. IGF1R, insulin-like growth factor 1 receptor; miR, microRNA; WT, wild-type; 3'UTR, 3' untranslated region; NC, negative control.

Figure 2. Expression of miR-194-5p in GBM tissues. (A) Levels of miR-194-5p were analyzed by the reverse transcription-quantitative polymerase chain reaction in 10 GBM tissues and the corresponding adjacent healthy tissues. (B) The mean values of miR-194-5p in the 10 tissues were calculated. The data are presented as the mean ± standard deviation. Experiments were repeated at least three times. *P<0.05 vs. the normal tissues. miR, microRNA; GBM, glioblastoma multiforme.
level was observed to be reduced 48 h following transfection (Fig. 1C). The results indicated that miR-194-5p may serve a role in GBM via IGF1R, thus miR-194-5p was selected for further study.
Decreased miR-194-5p in GBM tissues. miR-194-5p levels were evaluated in 10 GBM tissues and compared with the miR-194-5p levels in the 10 corresponding adjacent normal tissues. All the GBM tissues were observed to express decreased miR-194-5p levels compared with the corresponding adjacent normal tissues (Fig. 2A). The mean levels of the 10 GBM tissues also exhibited a decreased level of miR-194-5p compared with the normal tissues (Fig. 2B).

Effect of miR-194-5p mimics on GBM cell growth and apoptosis. miR-194-5p was overexpressed in GBM cells to test the function of miR-194-5p. The miR-194-5p levels in U373, U118 and NHA cells were analyzed by RT-qPCR, and it was observed that U373 and U118 cells expressed decreased levels of miR-194-5p compared with NHA cells (Fig. 3A). miR-194-5p was successfully overexpressed in U373 and U118 cells by miR-194-5p mimic transfection (Fig. 3B). MTT analysis revealed that the miR-194-5p mimics inhibited the growth of U373 and U118 cells (Fig. 3C). The cellular apoptotic rate was analyzed 48 h following miR-194-5p mimic transfection, and it was observed that miR-194-5p upregulated the apoptotic rate of U373 and U118 cells (Fig. 3D).

Effect of miR-194-5p ASO on cell growth. miR-194-5p was successfully downregulated in U373 and U118 cells by miR-194-5p ASO transfection. After 48 h, the miR-194-5p levels in cells were analyzed by RT-qPCR (Fig. 4A). Cellular proliferation in the two cell lines was analyzed using the MTT assay, and it was observed that miR-194-5p ASO promoted the cellular proliferation of U373 and U118 cells (Fig. 4B).

Discussion

miR-194-5p inhibited cellular proliferation, invasion and migration in non-small cell lung cancer by targeting forkhead box A1 (26). In the present study, miR-194-5p was demonstrated to inhibit cellular proliferation and apoptosis in GBM by targeting IGF1R.

GBM immunotherpay studies observed that macrophages accumulate during GBM progression and may be targeted by inhibition of colony-stimulating factor-1 receptor (CSF-1R) (27,28). In clinical trials, several approaches to inhibit CSF-1R are currently being used, including antibodies and small molecules (29-31). Quail et al (32) studied acquired resistance to CSF-1R inhibition immunotherapy in glioma in 2016 and demonstrated that the phosphatidylinositol 3-kinase pathway activity was elevated in recurrent GBM, driven by macrophage-derived IGF1 and IGF1R. IGF1R inhibition with CSF-1R inhibition in recurrent tumors significantly prolonged overall survival in mice. In the present study, miR-194-5p was observed to target IGF1R in GBM cell lines. Therefore, it was hypothesized that miR-194-5p may be useful in GBM therapy. It was hypothesized that overexpression of miR-194-5p may inhibit tumor cell growth and promote cell apoptosis, and that inhibition of IGF1R may promote the effect of the macrophage-targeted immunotherapy. The role of miR-194-5p in macrophage-targeted immunotherapy requires further investigation.

In conclusion, the results of the present study demonstrated that miR-194-5p inhibited cellular proliferation and promoted cell apoptosis. The target gene of miR-194-5p is IGF1R. The present study demonstrated that miR-194-5p inhibited GBM cell growth and promoted apoptosis via IGF1R.

References

1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
2. Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453, 2007.
3. Ohgaki H and Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglialomas. J Neuropathol Exp Neurol 64: 479-489, 2005.
4. Ramakrishna R and Pisapia D: Recent molecular advances in our understanding of glioma. Cereus 7: e287, 2015.
5. Fisher JL, Schwartzbaum JA, Wrensch M and Wiemels JL: Epidemiology of brain tumors. Neurol Clin 25: 867-900, vii, 2007.
6. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO and Cairncross JG: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiosurgery Group; National Cancer Institute of Canada Clinical Trials Group: Changing paradigms—an update on the multidisciplinary management of malignant glioma. Oncologist 11: 165-180, 2006.
7. Oermann E, Collins BT, Erickson KT, Yu X, Lei S, Suy S, Hanscom HM, Kim J, Park HU, Eldabi A, et al: CyberKnife enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures. J Hematol Oncol 3: 2, 2010.
8. Ottenhausen M, Krieg SM, Meyer B and Ringel F: Functional preoperative and intraoperative mapping and monitoring; increasing safety and efficacy in glioma surgery. Neurosurg Focus 38: E3, 2015.
9. Paw I, Carpenter RC, Watabe K, Debinisi W and Lo HW: Mechanisms regulating glioma invasion. Cancer Lett 362: 1-7, 2015.
10. Xie B, Ding Q, Han H and Wu D: miRCancer: A microRNA-cancer association database constructed by text mining on literature. Bioinformatics 29: 638-644, 2013.
11. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Brien KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
12. Shimono Y, Zabala M, Cho RW, Lobo N, Dalepa P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, et al: Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138: 592-603, 2009.
13. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
14. Babae N, Bourrajaj M, Liu Y, Van Beijnum JR, Cerisoli F, Scaria PV, Verheul M, Van Berkel MP, Pieters EH, Van Haasteren RJ, et al: Systemic microRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. Oncotarget 5: 6687-6700, 2014.
15. Hwang H and Mendell J: microRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94: 776-780, 2006.
16. Frankel LB, Wen J, Lees M, Hayer-Hansen M, Farkas T, Krogh A, Jäättelä M and Lund AH: microRNA-101 is a potent inhibitor of autophagy. EMBO J 30: 4628-4641, 2011.
17. Zhang H, Li Y and Lai M: The microRNA network and tumor metastasis. Oncogene 29: 937-948, 2010.
18. Dontula R, Divasarapu A, Chetty C, Pannuru P, Herbert E, Ozer H and Lakka SS: microRNA 203 modulates glioma cell migration via Robo1/ERK/MMP-9 signaling. Genes Cancer 4: 285-296, 2013.
19. LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137, 2003.
20. Denduluri SK, Idowu O, Wang Z, Liao Y, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L and Luu HH: Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis 2: 13-25, 2015.
21. Maris J, D’Haene N, Trépant AL, Le Mercier M, Sauvage S, Allard J, Rorive S, Demetter P, Deaceaetecker C and Salmon I: IGF-IR: A new prognostic biomarker for human glioblastoma. Br J Cancer 113: 729-737, 2015.
22. Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA, Reddel RR and Freshney RI: Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer 127: 1-8, 2010.

23. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) method. Methods 25: 402-408, 2001.

24. Vermes I, Haanen C, Steffens-Nakken H and Reutellingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39-51, 1995.

25. Song B, Zhang C, Li G, Jin G and Liu C: miR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88. Cell Physiol Biochem 35: 1167-1177, 2015.

26. Zhu X, Li D, Yu F, Jia C, Xie J, Ma Y, Fan S, Cai H, Luo Q, Lv Z and Fan L: miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein. Oncotarget 7: 13139-13152, 2016.

27. Josephs DH, Bax HJ and Karagiannis SN: Tumour-associated macrophage polarisation and re-education with immunotherapy. Front Biosci (Elite Ed) 7: 293-308, 2015.

28. Seton-Rogers S: Tumour microenvironment: Teaching old macrophages new tricks. Nat Rev Cancer 13: 753, 2013.

29. Ruffell B and Coussens LM: Macrophages and therapeutic resistance in cancer. Cancer Cell 27: 462-472, 2015.

30. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, et al: Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25: 846-859, 2014.

31. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielewski B, Staddon AP, Cohn AL, Shapiro GI, et al: Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med 373: 428-437, 2015.

32. Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, Holland EC, Sutton JC and Joyce JA: The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352: aad3018, 2016.